Shares of Alvotech (ALVO) plunged 5.80% in pre-market trading on Thursday following the release of the company's fourth-quarter and full-year 2024 financial results. The biopharmaceutical company's performance painted a mixed picture, with strong revenue growth overshadowed by a larger-than-anticipated annual loss.
For the fourth quarter, Alvotech reported a loss of $0.24 per share, which was better than the analysts' expectations of a $0.39 per share loss. The company's revenue surged by 177.4% to $153.34 million, significantly surpassing the forecasted $115.33 million. Despite this positive surprise, investors seemed more focused on the full-year results.
Alvotech's full-year 2024 performance showed a GAAP loss of $0.87 per share, missing the analyst consensus estimate of $0.55 per share by a considerable margin. However, the annual revenue of $492 million beat expectations of $455.53 million, representing a massive 438.09% increase from the previous year. The market's negative reaction suggests that investors are concerned about the company's profitability despite its impressive top-line growth. In a separate announcement, Alvotech appointed Dr. Balaji V. Prasad as its new Chief Strategy Officer, which could potentially influence the company's future direction and performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.